Hope S. Rugo, MD, discussed KEYNOTE-B49 data showing pembrolizumab plus chemotherapy improved PFS in PD-L1-positive HR+/HER2- breast cancer.
|Articles|June 1, 1997
Oncology NEWS International
- Oncology NEWS International Vol 6 No 6
- Volume 6
- Issue 6
Hoechst Marion Roussel Funds Outcomes Research
KANSAS CITY, Mo--Hoechst Marion Roussel is offering research grants totaling nearly $500,000 to fund health economics and outcomes studies through its 1997 ACCORD (A Company-wide Commitment to Outcomes Research and Development) program.
Advertisement
KANSAS CITY, Mo--Hoechst Marion Roussel is offering research grantstotaling nearly $500,000 to fund health economics and outcomes studiesthrough its 1997 ACCORD (A Company-wide Commitment to Outcomes Researchand Development) program.
Researchers and institutions interested in applying for grants can receivea program brochure and application form by calling ACCORD coordinator MaryMiller at 816-966-3780. The deadline for proposals is August 15, 1997.
Articles in this issue
over 29 years ago
Studies of Counselings' Impact on Survival Challengedover 29 years ago
Telomerase Activity Potential Marker for Bladder Cancerover 29 years ago
Writing Genetic Testing Guidelines Complex Endeavorover 29 years ago
AACR Meeting Sees Growth Spurt in Telomerase Researchover 29 years ago
DDT Appears to Activate Human Estrogen Receptorsover 29 years ago
Studies Highlight Role of bcl-2 Gene in Programmed Cell Deathover 29 years ago
Efficacy of BCG Maintenance in Bladder Cancer Is Confirmedover 29 years ago
Surgery Seen as Adjunct to Chemo in Some Invasive Breast Cancersover 29 years ago
Traveling Exhibit of Cancer Educational ResourcesAdvertisement
Related to this article
In a prospective cohort, a 3-gene blood model predicted 1-year castration resistance with an AUC of 0.89 in metastatic hormone-sensitive prostate cancer.
Rutika Mehta, MD, MPH, explains how she sequences MSI, HER2, claudin 18.2, and PD-L1 testing when tissue is limited in gastroesophageal cancer.
Dirk Schadendorf, MD, outlineed which patients with BRAF V600–mutant melanoma, including those with brain metastases, may be candidates for triplet therapy.
Dirk Schadendorf, MD, discussed final STARBOARD data with encorafenib, binimetinib, and pembrolizumab and its role in BRAF V600–mutant melanoma care.
Heath Skinner, MD, PhD, discussed the 3 considerations that determine which new radiation oncology service lines his network chooses to build.
Dwight H. Owen, MBBCh, MS, discussed why severe immune-related toxicities remain hard to predict as immunotherapy combinations expand in lung cancer.
Mingjia Li, MD, discussed the limitations of current biomarkers in selecting patients with resectable NSCLC for neoadjuvant chemoimmunotherapy.
Advertisement
Advertisement
Trending on CancerNetwork
1
Blood mRNA Model Predicts Castration Resistance in Metastatic Prostate Cancer
2
Prioritizing Biomarker Testing to Conserve Tissue in Gastroesophageal Cancer
3
Choosing Between Triplet Therapy and Immunotherapy in BRAF-Mutant Melanoma
4
Triplet Therapy Emerges as a First-Line Option in BRAF V600–Mutant Melanoma
5